New York State Teachers Retirement System Has $19 Million Stock Position in Hologic, Inc. (NASDAQ:HOLX)

New York State Teachers Retirement System lowered its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 10.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 265,905 shares of the medical equipment provider's stock after selling 31,525 shares during the period. New York State Teachers Retirement System owned about 0.11% of Hologic worth $18,999,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Hologic by 1.4% in the first quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider's stock valued at $2,141,919,000 after purchasing an additional 381,608 shares in the last quarter. BlackRock Inc. grew its position in shares of Hologic by 1.2% in the 1st quarter. BlackRock Inc. now owns 23,762,174 shares of the medical equipment provider's stock valued at $1,917,607,000 after acquiring an additional 282,787 shares during the period. State Street Corp grew its position in shares of Hologic by 0.8% in the 1st quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider's stock valued at $877,794,000 after acquiring an additional 94,561 shares during the period. Macquarie Group Ltd. grew its position in shares of Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider's stock valued at $435,485,000 after acquiring an additional 4,363,687 shares during the period. Finally, Victory Capital Management Inc. grew its position in shares of Hologic by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider's stock valued at $335,763,000 after acquiring an additional 393,371 shares during the period. Institutional investors own 94.73% of the company's stock.

Insider Activity

In other news, CFO Karleen Marie Oberton sold 14,940 shares of the business's stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at approximately $7,793,700. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares of the company's stock, valued at approximately $119,802.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of Hologic stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. In the last ninety days, insiders sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is currently owned by corporate insiders.

Hologic Stock Performance

Hologic stock traded up $1.03 during midday trading on Tuesday, hitting $78.41. The company's stock had a trading volume of 1,336,385 shares, compared to its average volume of 1,827,376. The company has a 50-day moving average price of $75.30 and a two-hundred day moving average price of $72.21. The company has a market cap of $18.41 billion, a price-to-earnings ratio of 37.16, a PEG ratio of 2.64 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. Hologic, Inc. has a 1-year low of $64.02 and a 1-year high of $87.88.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business's revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.07 EPS. As a group, sell-side analysts predict that Hologic, Inc. will post 4.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. StockNews.com downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Friday, March 8th. Raymond James lifted their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an "outperform" rating in a report on Friday, February 2nd. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. William Blair reaffirmed an "outperform" rating on shares of Hologic in a report on Friday, February 2nd. Finally, Needham & Company LLC lifted their target price on shares of Hologic from $83.00 to $90.00 and gave the stock a "buy" rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.